ADAGENE INCORPORATION revenue for the last year amounted to 16.41 M EUR, the most of which — 16.41 M EUR — came from its highest performing source at the moment, Monoclonal Antibody Drugs, the year earlier bringing 8.68 M EUR. The greatest contribution to the revenue figure was made by China — last year it brought ADAGENE INCORPORATION 16.41 M EUR, and the year before that — 8.68 M EUR.